{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:04:44Z","timestamp":1781071484469,"version":"3.54.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC). However, its post-marketing safety profile in routine practice remains incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System from Q2 2024 to Q3 2025, with a descriptive cross-database comparison using WHO-VigiAccess. Disproportionality analyses were performed using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms. Clinical priority scoring, subgroup analysis, time-to-onset analysis, multivariable logistic regression, and interpretable machine learning with SHAP (SHapley Additive exPlanations) were further applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 942 reports with tarlatamab as the primary suspect drug were identified, comprising 1,346 adverse events. At the preferred-term level, 30 signals met all four disproportionality criteria. The most frequent and strongest signals were cytokine release syndrome (CRS; n = 201; ROR 223.84, 95% CI 192.15\u2013260.77) and immune effector cell-associated neurotoxicity syndrome (ICANS; n = 106; ROR 312.43, 95% CI 254.68\u2013383.26). Common additional signals included pyrexia, dysgeusia, hypotension, and ageusia. Potentially under-recognized events, such as intestinal perforation, dyspnoea at rest, and incontinence, were also detected. Most adverse events occurred early after treatment initiation, with a median time to onset of 3 days; CRS and ICANS both showed a median onset of 1 day. In multivariable analysis, concomitant medication use was associated with higher reported odds of CRS (OR 2.551, 95% CI 1.353\u20134.811), whereas reports from Japan and the year 2025 were associated with lower reported odds. The CRS report-level classification model showed acceptable discrimination (AUC 0.733), whereas the best machine-learning model for adverse events of immune disorders classification within FAERS reports showed only modest performance (validation AUC 0.639). SHAP analysis indicated that country and therapy type contributed more to model output than age and sex, suggesting that the model primarily captured reporting context and treatment complexity rather than intrinsic biological susceptibility. Cross-database comparison with WHO-VigiAccess showed a broadly concordant reporting pattern, with CRS and ICANS remaining the most commonly reported toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Post-marketing data indicate that tarlatamab has a distinct safety profile dominated by early-onset immune-mediated and neurologic toxicities, particularly CRS and ICANS. Early monitoring and prompt supportive management during initial treatment cycles are essential. These findings broaden current knowledge of tarlatamab safety in real-world practice and support prospective studies to pharmacovigilance-based signal stratification and monitoring strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1844248","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:42:15Z","timestamp":1781070135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events"],"prefix":"10.3389","volume":"17","author":[{"given":"Yingyong","family":"Ou","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxian","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/pgs-2023-0199","article-title":"Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy","volume":"25","author":"Abudahab","year":"2024","journal-title":"Pharmacogenomics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1093\/bioinformatics\/btaa1009","article-title":"glmGamPoi: fitting gamma-poisson generalized linear models on single cell count data","volume":"36","author":"Ahlmann-Eltze","year":"2021","journal-title":"Bioinformatics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/nejmoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s11096-025-01975-3","article-title":"Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool","volume":"47","author":"Algarvio","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107555","DOI":"10.1016\/j.compbiomed.2023.107555","article-title":"The enlightening role of explainable artificial intelligence in medical and healthcare domains: a systematic literature review","volume":"166","author":"Ali","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.anclin.2015.05.003","article-title":"Physiology considerations in geriatric patients","volume":"33","author":"Alvis","year":"2015","journal-title":"Anesthesiol. Clin."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"B10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv."},{"key":"B11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-World outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ph15030298","article-title":"A Sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases","volume":"15","author":"Brabete","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12933-024-02538-y","article-title":"Exploring the prognostic impact of triglyceride-glucose index in critically ill patients with first-ever stroke: insights from traditional methods and machine learning-based mortality prediction","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31689","DOI":"10.1038\/s41598-025-17232-6","article-title":"A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting System database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/ijerph16020194","article-title":"Urinary and faecal incontinence: point prevalence and predictors in a university Hospital","volume":"16","author":"Condon","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e57824","DOI":"10.2196\/57824","article-title":"Applying AI to structured real-world data for pharmacovigilance purposes: scoping review","volume":"26","author":"Dimitsaki","year":"2024","journal-title":"J. Med. Internet Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2010.07.001","article-title":"Prognostic impact of comorbidity in elderly lung cancer patients: use and comparison of two scores","volume":"72","author":"Giron\u00e9s","year":"2011","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1561020","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/jamia\/ocz228","article-title":"A tutorial on calibration measurements and calibration models for clinical prediction models","volume":"27","author":"Huang","year":"2020","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3724\/abbs.2023080","article-title":"Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance","volume":"55","author":"Jin","year":"2023","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10097","DOI":"10.1007\/s00210-026-05028-y","article-title":"Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database","volume":"399","author":"Jin","year":"2026","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cllc.2025.11.018","article-title":"Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: Real-World insights into Step-Up dosing and prophylactic tocilizumab use","volume":"27","author":"Joshi","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/cancers17132256","article-title":"Redefining the fight against SCLC: standards, innovations, and new Horizons","volume":"17","author":"Kemper","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ajpath.2021.11.003","article-title":"Genetic deletion of vascular endothelial growth factor receptor 2 in endothelial cells leads to immediate disruption of tumor vessels and aggravation of hypoxia","volume":"192","author":"Kido","year":"2022","journal-title":"Am. J. Pathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40262-025-01499-z","article-title":"Population pharmacokinetics of tarlatamab, a half-life extended DLL3-Directed bispecific T-Cell engager in patients with previously treated small cell lung cancer","volume":"64","author":"Kong","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e70179","DOI":"10.1002\/cncr.70179","article-title":"Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results","volume":"132","author":"Lawrence","year":"2026","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","article-title":"Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database","volume":"24","author":"Le","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1713141","DOI":"10.3389\/fphar.2025.1713141","article-title":"Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess","volume":"16","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12903-025-07528-4","article-title":"An interpretable machine learning model using SHapley Additive exPlanations for preoperative cervical lymph node metastasis risk stratification in tongue squamous cell carcinoma: a multicenter study","volume":"26","author":"Li","year":"","journal-title":"BMC Oral Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41746-025-02173-1","article-title":"Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology","volume":"9","author":"Li","year":"2026","journal-title":"NPJ Digit. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1502047","DOI":"10.3389\/fphar.2024.1502047","article-title":"Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1586361","DOI":"10.3389\/fimmu.2025.1586361","article-title":"Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cllc.2025.09.008","article-title":"Tarlatamab-Induced Tumor lysis syndrome in small cell carcinoma: case series","volume":"27","author":"Lobsiger","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"108495","DOI":"10.1016\/j.biotechadv.2024.108495","article-title":"Interpretable and explainable predictive machine learning models for data-driven protein engineering","volume":"79","author":"Medina-Ortiz","year":"2025","journal-title":"Biotechnol. Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e068956","DOI":"10.1136\/bmjopen-2022-068956","article-title":"Urinary incontinence in older men: protocol for a scoping review of risk factors","volume":"13","author":"Olagundoye","year":"2023","journal-title":"BMJ Open"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/jco.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-Targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1634\/theoncologist.10-6-399","article-title":"Treatment of small cell lung cancer in the elderly","volume":"10","author":"Rossi","year":"2005","journal-title":"Oncologist"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e35738","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-017-3898-y","article-title":"Influence of cancer and acute inflammatory disease on taste perception: a clinical pilot study","volume":"26","author":"Schalk","year":"2018","journal-title":"Support Care Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40290-024-00549-4","article-title":"Disproportionality analysis and causal inference in drug safety","volume":"39","author":"Scosyrev","year":"2025","journal-title":"Pharm. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.pupt.2025.102383","article-title":"Pharmacovigilance of five commonly used antibiotics in acute exacerbations of COPD (AECOPD): analysis of the FDA adverse event reporting system database","volume":"90","author":"Shen","year":"2025","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front. Public Health"},{"key":"B57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12877-021-02242-6","article-title":"Smell, taste and trigeminal disorders in a 65-year-old population","volume":"21","author":"Sodal","year":"2021","journal-title":"BMC Geriatr."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1186\/s12885-025-14696-7","article-title":"Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database","volume":"25","author":"Sui","year":"2025","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21037\/tlcr-23-115","article-title":"Tarlatamab: the promising immunotherapy on its way from the lab to the clinic","volume":"12","author":"Tang","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","article-title":"Identification of substandard medicines via disproportionality analysis of individual case safety reports","volume":"40","author":"Trippe","year":"2017","journal-title":"Drug Saf."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B62","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.lungcan.2025.108801","article-title":"Safety evaluation of tarlatamab: a pharmacovigilance study based on the FAERS database","volume":"214","author":"Wang","year":"2026","journal-title":"Lung Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"106030","DOI":"10.1016\/j.ijmedinf.2025.106030","article-title":"Development and validation of a machine learning model for early screening of high-risk mild cognitive impairment from the multi-cohort data","volume":"203","author":"Wu","year":"2025","journal-title":"Int. J. Med. Inf."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04871-3","article-title":"Predicting amyotrophic lateral sclerosis stage based on multi-parameter ultrasound: development and validation of an interpretable machine learning model","author":"Yang","year":"2026","journal-title":"BMC Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"114248","DOI":"10.1016\/j.biopha.2023.114248","article-title":"Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer","volume":"159","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"108870","DOI":"10.1016\/j.lungcan.2025.108870","article-title":"A multi-institutional perspective on tarlatamab administration and management of CRS\/ICANS","volume":"211","author":"Zhang","year":"2026","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1844248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:42:17Z","timestamp":1781070137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1844248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":66,"alternative-id":["10.3389\/fphar.2026.1844248"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1844248","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1844248"}}